Two studies highlight the role of the heat shock response in initiating and maintaining cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dai, C., Whitesell, L., Rogers, A.B. & Lindquist, S. Cell 130, 1005–1018 (2007).
Kang, B.H. et al. Cell 131, 257–270 (2007).
Powers, M.V. & Workman, P. FEBS Lett. 581, 3758–3769 (2007).
Sharp, S. & Workman, P. Adv. Cancer Res. 95, 323–348 (2006).
Chiosis, G. & Neckers, L. ACS Chem. Biol. 1, 279–284 (2006).
Workman, P. et al. Ann. NY Acad. Sci. 1113, 202–216 (2007).
Banerji, U. et al. J. Clin. Oncol. 23, 4152–4161 (2005).
Hayden, P.J. et al. Curr. Opin. Hematol. 14, 609–615 (2007).
Hahn, J.S. et al. Mol. Cell. Biol. 24, 5249–5256 (2004).
Xiao, X. et al. EMBO J. 18, 5943–5952 (1999).
Hsu, A.L. et al. Science 300, 1142–1145 (2003).
Whitesell, L. & Lindquist, S.L. Nat. Rev. Cancer 5, 761–772 (2005).
Gatenby, R.A. & Gillies, R.J. Nat. Rev. Cancer 4, 891–899 (2004).
Plescia, J. et al. Cancer Cell 7, 457–468 (2005).
Green, D.R. & Kroemer, G. Science 305, 626–629 (2004).
Powers, M.V. & Workman, P. Nat. Chem. Biol. 3, 455–457 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
P.W. has developed HSP90 inhibitors that are licensed to Vernalis and Novartis. He has received research funding from Vernalis and is a consultant to Novartis.
Rights and permissions
About this article
Cite this article
Workman, P., de Billy, E. Putting the heat on cancer. Nat Med 13, 1415–1417 (2007). https://doi.org/10.1038/nm1207-1415
Issue Date:
DOI: https://doi.org/10.1038/nm1207-1415